Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Limited Asian Fallout From Pfizer-Allergan Merger?

This article was originally published in PharmAsia News

Executive Summary

As far as Asian and emerging pharma markets go, it is clear that Pfizer will be the dominant partner in the planned $160bn merger with Allergan. The US firm has a broad reach in these areas that Allergan will be looking to tap into, and major restructuring in big regional markets such as China and Japan looks unlikely.

You may also be interested in...



Trump Or Biden, China Determined To Narrow Health Gap With US

Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.

Hit And Miss First Half For Takeda

While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.

Affordable PD-1 From China? CStone Going Global With EQRx Onboard

As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel